Risperidon und Olanzapin in Depotformulierung – Effekte und spezifische Nebenwirkungen

Abstract

Until recently, long-acting injectable formulations of antipsychotics have been available in Germany only for older, conventional treatments. Since 2002, the only approved long-acting injection developed for an atypical antipsychotic has been long-acting risperidone (Risperdal® Consta®). The approval of another long-acting atypical antipsychotic (olanzapine long-acting injection, OLAI) is now also granted. First long-term data were presented by Detke C. Holland et al. on the 26 th Collegium Internationale Neuro-Psychopharmacologicum (CINP) in July 2008 in Munich. A review on efficacy and safety of OLAI has recently been published in the International Journal of Clinical Practice. Direct comparison data between the two drugs are missing. Given the fundamental importance of long-acting injection forms of atypical antipsychotics, however, an early consideration of the two substances in depot formulation is already important. Results under OLAI and long-acting risperidone allow a first careful comparative assessment with regard to both efficacy and tolerability and specific possible side effects.